Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes novel therapies for the treatment of pain. The company’s lead product candidate, DSUVIA (known as ARX-04 outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It pipeline also includes ZALVISO, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx incorporates non-invasive, sublingual formulation technology to deliver highly drugs of its product candidates. The company commercializes ZALVISO under license agreement with Grunenthal in the European Union countries, Switzerland, Liechtenstein, Iceland, Norway, and Australia. AcelRx is headquartered in Redwood City, California, the US. AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data... Research Beam Model: Research Beam Product ID: 1725695 250 USD New
AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile
 
 

AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile

  • Category : Medical Devices
  • Published On : July   2017
  • Pages : 33
  • Publisher : GlobalData
 
 
 
Summary

AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes novel therapies for the treatment of pain. The company’s lead product candidate, DSUVIA (known as ARX-04 outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It pipeline also includes ZALVISO, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx incorporates non-invasive, sublingual formulation technology to deliver highly drugs of its product candidates. The company commercializes ZALVISO under license agreement with Grunenthal in the European Union countries, Switzerland, Liechtenstein, Iceland, Norway, and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
AcelRx Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Equity Offering 10
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 10
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 11
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 12
AcelRx Pharma Completes IPO Of US$40 Million 13
Asset Transactions 15
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 15
AcelRx Pharmaceuticals Inc - Key Competitors 17
Key Employees 18
Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 20
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 22
Nov 01, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results 24
Jul 28, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results 26
Mar 07, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results 29
Corporate Communications 31
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 31
Mar 29, 2016: AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
List of Tables
AcelRx Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 1
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AcelRx Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 10
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 11
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 12
AcelRx Pharma Completes IPO Of US$40 Million 13
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 15
AcelRx Pharmaceuticals Inc, Key Competitors 17
AcelRx Pharmaceuticals Inc, Key Employees 18
AcelRx Pharmaceuticals Inc, Subsidiaries 19
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter